Myoview receives approvable letter

Amersham International subsidiary Medi-Physics of Arlington Heights,IL, has received an approvable letter from the Food and Drug Administrationfor Myoview, its technetium-based cardiac imaging agent. Myoviewwill complement Amersham's thallium-201-based imaging productand will compete with Du Pont Merck's Cardiolite agent. Medi-Physicswill emphasize the fast clearance of Myoview as well as the product'sease of use compared to thallium agents. Final FDA approval isexpected within a few months, according to the company.